Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Other Accumulated Expenses (2016 - 2022)

Historic Other Accumulated Expenses for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $3.8 million.

  • Avadel Pharmaceuticals' Other Accumulated Expenses rose 15540.45% to $3.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $3.8 million, marking a year-over-year increase of 15540.45%. This contributed to the annual value of $5.3 million for FY2021, which is 134.62% up from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Other Accumulated Expenses of $3.8 million as of Q3 2022, which was up 15540.45% from $2.1 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $5.3 million during Q4 2021, with a 5-year trough of $1.4 million in Q1 2022.
  • Its 5-year average for Other Accumulated Expenses is $2.9 million, with a median of $3.1 million in 2018.
  • Per our database at Business Quant, Avadel Pharmaceuticals' Other Accumulated Expenses soared by 50971.52% in 2018 and then plummeted by 5712.62% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $3.6 million in 2018, then rose by 6.46% to $3.9 million in 2019, then soared by 34.19% to $5.2 million in 2020, then increased by 1.35% to $5.3 million in 2021, then decreased by 28.71% to $3.8 million in 2022.
  • Its Other Accumulated Expenses stands at $3.8 million for Q3 2022, versus $2.1 million for Q2 2022 and $1.4 million for Q1 2022.